CClinicalTrials.gg
Not yet recruitingNCT07073599Updated Jul 18, 2025

Increasing Midwifery Students' Awareness of Breast and Gynecological Cancers Using Creative Drama Method

An interventional study of Creative Drama Education in Creative Drama, sponsored by Ataturk University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2025-07-18.

Sponsored by Ataturk University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

The aim of this study is to raise awareness among midwifery students, who are a part of the female population and a professional group that plays a critical role in the early diagnosis of these types of cancer, which are of critical importance for women's health, through an active education method such as drama.

Read the detailed description

The study will involve 50 volunteer midwifery students between the ages of 18 and 35 studying at the Faculty of Health Sciences. Students will be randomized and assigned to experimental and control groups. Awareness levels of breast and gynecological cancers in both groups will be determined. Students in the intervention group will be administered a creative drama exercise. Data will be collected using a Personal Information Form, the Breast Cancer Awareness Scale, and the Gynecological Cancer Awareness Scale.

02

Conditions studied

  • Creative Drama

Keywords

  • Creative drama
  • Breast and gynecological cancers
  • Midwifery students
  • Awareness
03

In context

Lead sponsor

Ataturk University is the lead sponsor of 442 studies on the registry; 121 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Being between the ages of 18-35,
  • Not having any health problems,
  • Agreeing to participate in the study,

Exclusion criteria

Exclusion Criteria:

  • Students who are under 18 or over 35 years old.
  • Students who do not voluntarily agree to participate in the study will not be included in the study.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • No intervention
    Control Group

    The control group will receive routine training and no action will be taken.

  • Experimental
    Experimental Group

    Students in the intervention group will be given a creative drama session. This will evaluate the impact of creative drama training on breast and gynecological cancer awareness.

    Other: Creative Drama Education

Interventions

  • OtherCreative Drama Education

    This study is a pre-test/post-test controlled experimental design aimed at evaluating the effectiveness of creative drama education on awareness of breast and gynecological cancers. Students in the intervention group will receive creative drama-based training structured and implemented by the researcher. This training is designed to increase awareness of breast and gynecological cancers. The effectiveness of the training will be assessed by comparing participants' awareness levels before and after the intervention. For this purpose, the following data collection tools will be used: Personal Information Form Breast Cancer Awareness Scale Gynecological Cancers Awareness Scale The impact of the creative drama education on the awareness levels of students in the intervention group regarding breast and gynecological cancers will be evaluated through statistical analysis.

06

What researchers measure

Primary outcomes

  1. Personel Information Form

    The researcher will prepare a form based on literature information and will question the students' sociodemographic characteristics.

    Time frame: Baseline

  2. Gynecological Cancers Awareness Scale

    To assess women's knowledge levels about gynecological cancers, Dal and Ertem developed the Gynecological Cancer Awareness Scale (GCAAS) in 2017. The scale consists of 41 questions and four subscales. 10. The scale can only be applied to women. The Cronbach's alpha value of the scale is 0.944. Questions 20-41 of the scale determine "Awareness of Routine Check-up and Perception of Serious Illness in Gynecological Cancers," and the Cronbach's alpha value of this subscale is 0.979. Questions three through 11 of the scale determine "Awareness of Gynecological Cancer Risks," and the Cronbach's alpha value of this subscale is 0.843. Questions 14-19 of the scale determine "Awareness of Prevention of Gynecological Cancers," and the Cronbach's alpha value is 0.778. The first and second questions of the scale, as well as the 12th and 13th questions, determine "Early Diagnosis and Information Awareness in Gynecological Cancers," and the Cronbach's Alpha value is 0.708.

    Time frame: Baseline and up to 4 weeks

  3. Breast Cancer Awareness Scale

    The scale was developed by Rakkapao et al. (2016) for the early detection and prevention of breast cancer. It is easy to use and was designed as a self-report tool that allows researchers and practitioners to better understand women's breast cancer awareness levels. The original scale consists of five factors and 35 items. Adapted to our language by Altuntuğ et al. in 2021, the scale obtained a five-factor structure with 29 items. The subdimensions of the scale were found to have good internal consistency. The Cronbach's alpha internal consistency coefficients for the subdimensions of the scale were 0.87 for Knowledge of Risk Factors, 0.88 for Knowledge of Signs and Symptoms, 0.81 for Breast Cancer Prevention Attitudes, 0.78 for Barriers to Breast Screening, and 0.61 for Health Behavior Related to Breast Cancer Awareness.

    Time frame: Baseline and up to 4 weeks

07

Study locations

1 site
  • Ataturk University Faculty of Health Sciences
    Erzurum, Center 25000, Turkey (Türkiye)
08

References and documents

Publications

  • Erci B, Karabulut N. Appraising the self-assessed support needs of Turkish women with breast cancer. Eur J Cancer Care (Engl). 2007 Mar;16(2):137-43. doi: 10.1111/j.1365-2354.2006.00721.x. PubMed 17371422 ↗
  • Sayar SE, Barbak ZD. Effect of gynecological and breast cancer education using a creative drama method on midwifery students' awareness: a randomized controlled trial. BMC Nurs. 2026 Feb 13;25(1):261. doi: 10.1186/s12912-026-04407-3. PubMed 41688990 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07073599
Lead sponsor
Ataturk University
Responsible party
Zülbiye demir barbak (Lecturer, Ataturk University) — Principal investigator
First posted
Jul 18, 2025
Start date
Aug 1, 2025 (estimated)
Primary completion
Nov 1, 2025 (estimated)
Completion
Feb 1, 2026 (estimated)
Last update
Jul 18, 2025

Study contacts

Zülbiye DEMİR BARBAK, 1
Contact
zulbiye.demir@atauni.edu.tr
+905435164229
Sultan Esra SAYAR, Lecturer
Contact
esra.tedik@atauni.edu.tr
+905302935474
Zülbiye DEMİR BARBAK, 1
principal investigator · Ataturk University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion